Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (15041)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 28, 2016 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Pejnovic N, Jeftic I, Jovicic N, Arsenijevic N, Lukic ML. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis. World J Gastroenterol 2016; 22(44): 9706-9717 [PMID: 27956794 DOI: 10.3748/wjg.v22.i44.9706] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i44/9706.htm |
| Number | Citing Articles |
| 1 |
Hee-Won Moon, Mikyoung Park, Mina Hur, Hanah Kim, Won Hyeok Choe, Yeo-Min Yun. Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases. Annals of Laboratory Medicine 2018; 38(4): 331 doi: 10.3343/alm.2018.38.4.331
|
| 2 |
Devaraj Ezhilarasan. Unraveling the pathophysiologic role of galectin‐3 in chronically injured liver. Journal of Cellular Physiology 2023; 238(4): 673 doi: 10.1002/jcp.30956
|
| 3 |
Sandra Rayego‐Mateos, José Luis Morgado‐Pascual, Cristina García‐Caballero, Iolanda Lazaro, Aleix Sala‐Vila, Lucas Opazo‐Rios, Sebastian Mas‐Fontao, Jesús Egido, Marta Ruiz‐Ortega, Juan Antonio Moreno. Intravascular hemolysis triggers NAFLD characterized by a deregulation of lipid metabolism and lipophagy blockade. The Journal of Pathology 2023; 261(2): 169 doi: 10.1002/path.6161
|
| 4 |
Wangyan Jiang, Zhelong Liu, Shaohua Liu, Tingting Du. Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1183075
|
| 5 |
Liang Chen, Chun Hu, Molly Hood, Juntao Kan, Xiaona Gan, Xue Zhang, Yi Zhang, Jun Du. An Integrated Approach Exploring the Synergistic Mechanism of Herbal Pairs in a Botanical Dietary Supplement: A Case Study of a Liver Protection Health Food. International Journal of Genomics 2020; 2020: 1 doi: 10.1155/2020/9054192
|
| 6 |
Hui Han, Romain Desert, Sukanta Das, Zhuolun Song, Dipti Athavale, Xiaodong Ge, Natalia Nieto. Danger signals in liver injury and restoration of homeostasis. Journal of Hepatology 2020; 73(4): 933 doi: 10.1016/j.jhep.2020.04.033
|
| 7 |
Manhal Izzy, Lisa B. VanWagner, Grace Lin, Mario Altieri, James Y. Findlay, Jae K. Oh, Kymberly D. Watt, Samuel S. Lee. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology 2020; 71(1): 334 doi: 10.1002/hep.30875
|
| 8 |
Stefano Fiorucci, Michele Biagioli, Eleonora Distrutti. Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacological Research 2018; 134: 289 doi: 10.1016/j.phrs.2018.07.014
|
| 9 |
Kyung Eun Kim, Hyun Joo Shin, Yeajin Ju, Youngae Jung, Hyeong Seok An, So Jeong Lee, Eun Ae Jeong, Jaewoong Lee, Geum-Sook Hwang, Gu Seob Roh. Intermittent Fasting Attenuates Metabolic-Dysfunction-Associated Steatohepatitis by Enhancing the Hepatic Autophagy–Lysosome Pathway. Nutrients 2023; 15(21): 4574 doi: 10.3390/nu15214574
|
| 10 |
S. Zhu, Z. Wu, W. Wang, L. Wei, H. Zhou. A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials. Journal of Endocrinological Investigation 2023; 47(4): 761 doi: 10.1007/s40618-023-02216-y
|
| 11 |
Melisa Kozaczek, Walter Bottje, Elizabeth Greene, Kentu Lassiter, Byungwhi Kong, Sami Dridi, Soheila Korourian, Reza Hakkak. Comparison of liver gene expression by RNAseq and PCR analysis after 8 weeks of feeding soy protein isolate- or casein-based diets in an obese liver steatosis rat model. Food & Function 2019; 10(12): 8218 doi: 10.1039/C9FO01387C
|
| 12 |
Tieshan Teng, Shuai Qiu, Yiming Zhao, Siyuan Zhao, Dequan Sun, Lingzhu Hou, Yihang Li, Ke Zhou, Xixi Yu, Changyong Yang, Yanzhang Li. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2022; 23(14): 7841 doi: 10.3390/ijms23147841
|
| 13 |
Evgenija Homsak, Damien Gruson. Soluble ST2: A complex and diverse role in several diseases. Clinica Chimica Acta 2020; 507: 75 doi: 10.1016/j.cca.2020.04.011
|
| 14 |
Andrew M. F. Johnson, Shaocong Hou, Pingping Li. Inflammation and insulin resistance: New targets encourage new thinking. BioEssays 2017; 39(9) doi: 10.1002/bies.201700036
|
| 15 |
Kosuke Kaji, Soichi Takeda, Satoshi Iwai, Norihisa Nishimura, Shinya Sato, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji. Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis. Antioxidants 2024; 13(11): 1415 doi: 10.3390/antiox13111415
|
| 16 |
Marina Boziki, Stergios A. Polyzos, Georgia Deretzi, Evangelos Kazakos, Panagiotis Katsinelos, Michael Doulberis, Georgios Kotronis, Evaggelia Giartza-Taxidou, Leonidas Laskaridis, Dimitri Tzivras, Elisabeth Vardaka, Constantinos Kountouras, Nikolaos Grigoriadis, Robert Thomann, Jannis Kountouras. A potential impact of Helicobacter pylori -related galectin-3 in neurodegeneration. Neurochemistry International 2018; 113: 137 doi: 10.1016/j.neuint.2017.12.003
|
| 17 |
Flavio A. Cadegiani. Dietary Interventions in Liver Disease. 2019; : 39 doi: 10.1016/B978-0-12-814466-4.00004-5
|
| 18 |
Tammy R. Chaudoin, Stephen J. Bonasera. Mice lacking galectin-3 (Lgals3) function have decreased home cage movement. BMC Neuroscience 2018; 19(1) doi: 10.1186/s12868-018-0428-x
|
| 19 |
Romain Itier, Maeva Guillaume, Jean‐Etienne Ricci, François Roubille, Nicolas Delarche, François Picard, Michel Galinier, Jérôme Roncalli. Non‐alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. ESC Heart Failure 2021; 8(2): 789 doi: 10.1002/ehf2.13222
|
| 20 |
Milica M. Borovcanin, Slavica M. Janicijevic, Ivan P. Jovanovic, Nevena Gajovic, Nebojsa N. Arsenijevic, Miodrag L. Lukic. IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis. Frontiers in Psychiatry 2018; 9 doi: 10.3389/fpsyt.2018.00271
|
| 21 |
Maria Gabriela Delgado, Jaume Bosch. HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials. Current Hepatology Reports 2019; 18(2): 164 doi: 10.1007/s11901-019-00461-5
|
| 22 |
R.J. Slack, R. Mills, A.C. Mackinnon. The therapeutic potential of galectin-3 inhibition in fibrotic disease. The International Journal of Biochemistry & Cell Biology 2021; 130: 105881 doi: 10.1016/j.biocel.2020.105881
|
| 23 |
Zijian Sun, Binxia Chang, Miaomiao Gao, Jiyuan Zhang, Zhengsheng Zou. IL-33-ST2 Axis in Liver Disease: Progression and Challenge. Mediators of Inflammation 2017; 2017: 1 doi: 10.1155/2017/5314213
|
| 24 |
Theodora Oikonomou, Ioannis Goulis, Fani Ntogramatzi, Zoi Athanasiadou, Eleni Vagdatli, Evangelos Akriviadis, Evangelos Cholongitas. Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis. Digestive and Liver Disease 2019; 51(12): 1692 doi: 10.1016/j.dld.2019.05.030
|
| 25 |
Linh Pham, Leonardo Baiocchi, Lindsey Kennedy, Keisaku Sato, Vik Meadows, Fanyin Meng, Chiung‐Kuei Huang, Debjyoti Kundu, Tianhao Zhou, Lixian Chen, Gianfranco Alpini, Heather Francis. The interplay between mast cells, pineal gland, and circadian rhythm: Links between histamine, melatonin, and inflammatory mediators. Journal of Pineal Research 2021; 70(2) doi: 10.1111/jpi.12699
|
| 26 |
Tea Lund Laursen, Anders Mellemkjær, Holger Jon Møller, Henning Grønbæk, Konstantin Kazankov. Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. Expert Opinion on Therapeutic Targets 2022; 26(8): 697 doi: 10.1080/14728222.2022.2132145
|
| 27 |
Mohammadjavad Sotoudeheian. Galectin-3 and Severity of Liver Fibrosis in Metabolic
Dysfunction-Associated Fatty Liver Disease. Protein & Peptide Letters 2024; 31(4): 290 doi: 10.2174/0109298665301698240404061300
|
| 28 |
Atef Al Attar, Ani Antaramian, Mazen Noureddin. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Review of Clinical Pharmacology 2021; 14(4): 457 doi: 10.1080/17512433.2021.1894127
|
| 29 |
Pio Conti, Gianpaolo Ronconi, Spyridon K. Kritas, Alessandro Caraffa, Theoharis C. Theoharides. Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could Be Beneficial. Canadian Journal of Diabetes 2018; 42(5): 568 doi: 10.1016/j.jcjd.2018.01.008
|
| 30 |
Kristiaan Wouters, Alessia S. Cento, Katrien H. Gaens, Margee Teunissen, Jean L. J. M. Scheijen, Federica Barutta, Fausto Chiazza, Debora Collotta, Manuela Aragno, Gabriella Gruden, Massimo Collino, Casper G. Schalkwijk, Raffaella Mastrocola. Deletion of RAGE fails to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-96859-7
|
| 31 |
Mei-Juan Sun, Zhan-Qi Cao, Ping Leng. The roles of galectins in hepatic diseases. Journal of Molecular Histology 2020; 51(5): 473 doi: 10.1007/s10735-020-09898-1
|
| 32 |
Ivan Srejovic, Dragica Selakovic, Nemanja Jovicic, Vladimir Jakovljević, Miodrag L. Lukic, Gvozden Rosic. Galectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior. Biomolecules 2020; 10(5): 798 doi: 10.3390/biom10050798
|
| 33 |
Elke Roeb. Interleukin-13 (IL-13)—A Pleiotropic Cytokine Involved in Wound Healing and Fibrosis. International Journal of Molecular Sciences 2023; 24(16): 12884 doi: 10.3390/ijms241612884
|
| 34 |
Svitlana Demyanets, Christoph Kaun, Alexandra Kaider, Walter Speidl, Manfred Prager, Stanislav Oravec, Philipp Hohensinner, Johann Wojta, Gersina Rega-Kaun. The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery. Cardiovascular Diabetology 2020; 19(1) doi: 10.1186/s12933-020-01001-y
|
| 35 |
Michael Kram. Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World Journal of Hepatology 2023; 15(2): 201-207 doi: 10.4254/wjh.v15.i2.201
|
| 36 |
Akira Hara, Masayuki Niwa, Kei Noguchi, Tomohiro Kanayama, Ayumi Niwa, Mikiko Matsuo, Yuichiro Hatano, Hiroyuki Tomita. Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules 2020; 10(3): 389 doi: 10.3390/biom10030389
|
| 37 |
Sanjana Nagraj, Spyros Peppas, Maria Gabriela Rubianes Guerrero, Damianos G Kokkinidis, Felipe I Contreras-Yametti, Sandhya Murthy, Ulrich P Jorde. Cardiac risk stratification of the liver transplant candidate: A comprehensive review. World Journal of Transplantation 2022; 12(7): 142-156 doi: 10.5500/wjt.v12.i7.142
|
| 38 |
Chung Eun Lee. Effects of Intermittent Fasting on Splenic Galectin-3 Protein Expression in High-fat Diet-fed Mice. Anatomy & Biological Anthropology 2023; 36(4): 209 doi: 10.11637/aba.2023.36.4.209
|
| 39 |
Katrin Neumann, Birgit Schiller, Gisa Tiegs. NLRP3 Inflammasome and IL-33: Novel Players in Sterile Liver Inflammation. International Journal of Molecular Sciences 2018; 19(9): 2732 doi: 10.3390/ijms19092732
|
| 40 |
家亮 范. Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Disease: Pathophysiological Mechanisms. Advances in Clinical Medicine 2024; 14(03): 1429 doi: 10.12677/acm.2024.143861
|
| 41 |
Suping Qin, Dexu Sun, Jingjing Mu, Daifu Ma, Renxian Tang, Yuanlin Zheng. Purple sweet potato color improves hippocampal insulin resistance via down-regulating SOCS3 and galectin-3 in high-fat diet mice. Behavioural Brain Research 2019; 359: 370 doi: 10.1016/j.bbr.2018.11.025
|
| 42 |
Ke Pei, Ting Gui, Dongfang Kan, Huichao Feng, Yanqiang Jin, Ying Yang, Qian Zhang, Ziwei Du, Zhibo Gai, Jibiao Wu, Yunlun Li. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. BioMed Research International 2020; 2020: 1 doi: 10.1155/2020/4020249
|
| 43 |
Alison C. Mackinnon, Dimitar Tonev, Brian Jacoby, Massimo Pinzani, Robert J. Slack. Galectin-3: therapeutic targeting in liver disease. Expert Opinion on Therapeutic Targets 2023; 27(9): 779 doi: 10.1080/14728222.2023.2258280
|
| 44 |
Nami Lee, Yu Jung Heo, Sung-E Choi, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Yup Kang, Kwan Woo Lee, Hae Jin Kim. Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. Biochemical and Biophysical Research Communications 2022; 588: 154 doi: 10.1016/j.bbrc.2021.12.065
|
| 45 |
Zhi Wang, Kailei Du, Nake Jin, Biao Tang, Wenwu Zhang. Macrophage in liver Fibrosis: Identities and mechanisms. International Immunopharmacology 2023; 120: 110357 doi: 10.1016/j.intimp.2023.110357
|
| 46 |
Darrell Pilling, Tejas R. Karhadkar, Richard H. Gomer, Qinghua Sun. A CD209 ligand and a sialidase inhibitor differentially modulate adipose tissue and liver macrophage populations and steatosis in mice on the Methionine and Choline-Deficient (MCD) diet. PLOS ONE 2020; 15(12): e0244762 doi: 10.1371/journal.pone.0244762
|
| 47 |
Melisa Kozaczek, Walter Bottje, Byungwhi Kong, Diyana Albataineh, Reza Hakkak. A Comparison of Short- and Long-Term Soy Protein Isolate Intake and Its Ability to Reduce Liver Steatosis in Obese Zucker Rats Through Modifications of Genes Involved in Inflammation and Lipid Transport. Journal of Medicinal Food 2021; 24(9): 1010 doi: 10.1089/jmf.2020.0180
|